


**Figure S1: Generation of a CXCL12 $\gamma$ -deficient mouse line**

**(A)** Schematic representation of the genomic *Cxcl12* locus organization (top) and corresponding mature mRNA splice variants (bottom).

**(B)** Nucleotide sequence alignment of the intron/exon 4 junction in CXCL12<sup>WT</sup> and CXCL12<sup>Δ $\gamma$</sup>  genomes. The corresponding amino acid sequence is shown in red. Introduction of a premature stop codon at the intron/exon 4 junction in CXCL12<sup>Δ $\gamma$</sup>  mice prevents translation of exon 4 (italicized red letters), resulting in production of the CXCL12 $\alpha$  isoform.


**(C)** Nucleotide sequence comparison of the exon 3/exon 4 junction in CXCL12<sup>WT</sup> and CXCL12<sup>Δ $\gamma$</sup>  spliced mRNAs. The engineered stop codon is positioned at the exon 3/exon 4 junction following splicing. The CXCL12 $\gamma$  C-terminal domain, encoded by exon 4, is present in CXCL12<sup>WT</sup> mice (red letters) but absent in CXCL12<sup>Δ $\gamma$</sup>  mice (italicized red letters).



**Figure S2: CXCL12 $\gamma$  controls the hematopoietic stem cell population size in bone marrow**

**(A)** Left: Flow cytometry gating strategy for identification of bone marrow hematopoietic stem cells (HSCs; Lin-Sca-1<sup>+</sup>c-Kit<sup>+</sup>CD48<sup>-</sup>CD150<sup>+</sup>). Right: Quantification of HSCs as percentage of CD45<sup>+</sup> cells in CXCL12<sup>wt</sup> and CXCL12<sup>Δy</sup> mice.

**(B)** Kinetics of donor-derived (CD45.2<sup>+</sup>) hematopoietic reconstitution in competitive bone marrow transplantation experiments. Shown are B cells (CD19<sup>+</sup>B220<sup>+</sup>),  $\alpha\beta$  T cells (CD3<sup>+</sup>TCR $\beta$ <sup>+</sup>), and non-B non-T cells at indicated time points post-transplantation in recipients of CXCL12<sup>wt</sup> or CXCL12<sup>Δy</sup> bone marrow cells.



**Figure S3: Impaired antibody affinity maturation in *CXCL12<sup>gagtm</sup>* mice**

**(A)** Somatic hypermutation analysis in memory B cells of *CXCL12<sup>gagtm</sup>* mice. AID-Cre × ROSA-lox-YFP reporter mice allow identification of cells with past GC experience. Mutation frequency distributions in the *J<sub>H</sub>4* intron are shown for naive B cells (*CD19<sup>+</sup>IgD<sup>hi</sup>CD95<sup>-</sup>CD38<sup>+</sup>YFP<sup>+</sup>*) isolated from one AID-Cre × ROSA-lox-YFP mouse (left panel), and memory B cells (*CD19<sup>+</sup>IgD<sup>-</sup>CD95<sup>-</sup>CD38<sup>+</sup>YFP<sup>+</sup>*) from 4 pooled wild-type and 4 pooled *CXCL12<sup>gagtm</sup>* recipient mice (right panel). The table shows mutation frequencies as percentage of total analyzed nucleotides.

**(B)** Somatic hypermutation following primary T cell-dependent immunization of *CXCL12<sup>gagtm</sup>* mice. Mutation frequency distributions in the *V<sub>H</sub>186.2* gene are shown for naive *IgD<sup>hi</sup>* B cells (left panel) and  $\lambda 1^+$  GC B cells (*CD19<sup>+</sup>IgD<sup>-</sup>CD38<sup>-</sup>CD95<sup>+</sup>*) from 5 pooled wild-type and 5 pooled *CXCL12<sup>gagtm</sup>* mice (right panel). The table shows mutation frequencies as percentage of total analyzed nucleotides.


**(C)** Frequency of W33L substitutions in *VH186.2* sequences from experiments in (B). Statistical significance determined by Fisher's exact test.

**(D)** Affinity maturation assessed by NP<sup>7</sup>/NP<sup>23</sup>-specific IgG1 titer ratios in sera collected at indicated time points following NP<sup>16</sup>-CGG immunization of 2 wild-type and 6 *CXCL12<sup>gagtm</sup>* mice.


## CXCL12 $\beta$

## CXCL12 $\gamma$

Bone Marrow



Brain (Dentate Gyrus)



**Figure S4: CXCL12 $\beta$  and CXCL12 $\gamma$  isoforms expression in bone marrow and brain**

Positive control showing robust detection of *Cxcl12 $\beta$*  transcripts in bone marrow (left) and *Cxcl12 $\gamma$*  transcripts in the brain dentate gyrus (right), confirming BaseScope probe specificity and sensitivity.